(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methanol | 1123169-46-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3-cyclopropyl-1,2,4-oxadiazol-5-yl)methanol
• CAS: 1123169-46-9
• 化学式: C₆H₈N₂O₂
• mdl: MFCD12138033
• 分子量: 140.142
• InChiKey: PGFKSKNXDXPOPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2(1H)-one 、 (3-cyclopropyl-1,2,4-oxadiazol-5-yl)methanol 在 di-tert-butyl (E)-azodicarboxylate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-cyclopropyl-5-(((3-fluoro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)oxy)methyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  [EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
  [FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)

  摘要：

  本发明涉及通式（I）的取代5-三氟甲基噁二唑化合物或其药学上可接受的盐。具体而言，本发明涉及一类芳基和杂环芳基取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。

  公开号：

  WO2017222951A1

文献信息

• 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11066396B2

  公开（公告）日：2021-07-20

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式(I)的取代的5-三氟甲基噁二唑化合物或其药学上可接受的盐。特别是，本发明涉及一类式 I 的芳基和杂芳基取代的 5-三氟甲基噁二唑化合物，其可作为 HDAC6 抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。
• 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3475275A1

  公开（公告）日：2019-05-01
• 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190185462A1

  公开（公告）日：2019-06-20

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
• [EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS<br/>[FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)
  申请人：MERCK SHARP & DOHME

  公开号：WO2017222951A1

  公开（公告）日：2017-12-28

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式（I）的取代5-三氟甲基噁二唑化合物或其药学上可接受的盐。具体而言，本发明涉及一类芳基和杂环芳基取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。